Veradigm (MDRX) Q4 2024 earnings summary

Executive summary

• Reviewed audited 2022 results and unaudited 2023–2024 revenue, adjusted EBITDA, and cash positions, with 2025 outlook provided.

• Fiscal 2023 revenue estimated at $620–$625M, net income of $62–$65M, and adjusted EBITDA of $139–$144M; 2024 revenue expected at $583–$588M, net loss of $46–$49M, and adjusted EBITDA of $85–$90M.

• Completed 2022 restatement, filed Form 10-K with restatements for 2020–2022, and detailed audit committee findings and remediation plans.

• Added four new independent directors and refreshed board leadership to strengthen oversight.

• Management remains focused on remediating internal control deficiencies, relisting common stock, and executing growth strategy.

Financial highlights

• 2023 unaudited revenue estimated at $620–$625M (including $19M customer settlements); recurring revenue ~80%.

• 2023 adjusted EBITDA estimated at $139–$144M, above prior guidance; net cash $239M at year-end.

• 2024 unaudited revenue estimated at $583–$588M (including $1M settlements), below prior guidance; recurring revenue ~80%.

• 2024 adjusted EBITDA estimated at $85–$90M, below guidance; net cash $87M at year-end.

• Provider segment revenue: $490–$493M (2023), $466–$469M (2024); Payer & Life Science: $130–$132M (2023), $117–$119M (2024).

Outlook and guidance

• 2025 revenue expected to be approximately flat versus 2024; growth from new customers/contracts and price increases offset by attrition.

• Net cash positive position anticipated throughout 2025; pursuing additional debt financing.

• No specific profitability guidance for 2025; cost realignment underway, with margin improvement expected in 2025 and more in 2026.